InMed Pharmaceuticals Inc. announced positive preclinical data from human brain organoid neuroinflammation models supporting the INM-901 Alzheimer's disease program, showing dose-dependent reduction of pro-inflammatory markers IL-6 and IL-8. The results translate prior animal model findings to human-relevant systems, de-risking the program ahead of a planned pre-IND meeting in Q3/2026 and Phase 1 trial in 2027.
Key takeaways
INM-901 demonstrated significant reduction in neuroinflammation in LPS/IFN-γ-induced and Alzheimer's disease human 3D brain organoid models.
Dose-dependent reduction of IL-6 and IL-8 pro-inflammatory markers observed.
Consistent anti-inflammatory effects align with prior in vivo mouse Alzheimer's model and ex vivo LPS model data.
Pre-IND meeting with FDA planned for Q3/2026; IND submission and Phase 1 trial targeted for 2027.
Studies conducted in collaboration with Stem Pharm, Inc.